Clinical use of radiation sensitizing agents.
D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D001761:Bleomycin / Q000627:therapeutic use; D001972:Bromodeoxycytidine / Q000627:therapeutic use; D001973:Bromodeoxyuridine / Q000008:administration & dosage / Q000627:therapeutic use; D001976:Bromouracil / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy; D003609:Dactinomycin / Q000627:therapeutic use; D004307:Dose-Response Relationship, Radiation; D005467:Floxuridine / Q000627:therapeutic use; D005472:Fluorouracil / Q000627:therapeutic use; D006258:Head and Neck Neoplasms / Q000532:radiotherapy; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007065:Idoxuridine / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D009374:Neoplasms, Experimental / Q000532:radiotherapy; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*
D000964:Antimetabolites, Antineoplastic; D011838:Radiation-Sensitizing Agents; D005467:Floxuridine; D001972:Bromodeoxycytidine; D001761:Bleomycin; D003609:Dactinomycin; D001976:Bromouracil; D001973:Bromodeoxyuridine; D007065:Idoxuridine; D005472:Fluorouracil; D006918:Hydroxyurea